Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) ROCE % : 0.00% (As of Sep. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eloxx Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.00%.

Eloxx Pharmaceuticals ROCE % Historical Data

The historical data trend for Eloxx Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals ROCE % Chart

Eloxx Pharmaceuticals Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-204.67

-109.40

-104.01

-252.66

-205.42

Eloxx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-301.31	-1,420.74	-	-	-

Eloxx Pharmaceuticals ROCE % Calculation

Eloxx Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-34.116	/	( ( (45.139 - 9.955)	+	(21.123 - 23.091) )	/ 2 )
	=	-34.116	/	( (35.184	+	-1.968)	/ 2 )
	=	-34.116	/	16.608
	=	-205.42 %

Eloxx Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	-13.428	/	( ( (5.993 - 21.251)	+	(6.042 - 23.466) )	/ 2 )
	=	-13.428	/	( ( -15.258	+	-17.424 )	/ 2 )
	=	-13.428	/	-16.341
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Eloxx Pharmaceuticals (OTCPK:ELOX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eloxx Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Watertown, MA, USA, 02472

Website

https://www.eloxxpharma.com

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.

Executives

Sumit Aggarwal	director, officer: PRESIDENT AND CEO	480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur	officer: HEAD OF R&D	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski	director	C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib	director	12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra	director	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur	director	210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts	director	197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p.	10 percent owner	4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404